Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort
复制标题
DOI：
10.3350/cmh.2014.20.3.261
复制
发表时间：
2014-09-01
影响因子：
8.9
通讯作者：
Park, Jun Yong
中科院分区：
文献类型：
--
作者：
Ahn, Sung Soo;Chon, Young Eun;Park, Jun Yong
背景/目的：本研究评估了富马酸替诺福韦二吡呋酯 (TDF) 在韩国初治慢性乙型肝炎 (CHB) 患者中长达 12 个月的抗病毒功效和安全性。方法：连续纳入 411 名接受 TDF 治疗至少 3 个月（中位数 5.6）的初治 CHB 患者。每3个月常规评估一次临床、生化、病毒学参数和治疗依从性。结果：中位年龄51.3岁，63.0%患者为男性，49.6%为HBeAg（+），210例患者患有肝硬化。基线 HBV DNA 中位数为 5.98 (SD 1.68) log(10) IU/mL。在完成第 48 周的患者中，83.3% 的患者达到了完全病毒学缓解（CVR、
Background/Aims: This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naive chronic hepatitis B (CHB) patients.Methods: A total of 411 treatment-naive CHB patients who had been treated with TDF for at least 3 months (median 5.6) were consecutively enrolled. Clinical, biochemical, virological parameters and treatment adherence were routinely assessed every 3 months.Results: The median age was 51.3 years, 63.0% of the patients were male, 49.6% were HBeAg (+), and 210 patients had liver cirrhosis. The median baseline HBV DNA was 5.98 (SD 1.68) log(10) IU/mL. Among the patients completing week 48, 83.3% had a complete virologic response (CVR,